Literature DB >> 22619258

Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel?

Ulrich Speck1, Bodo Cremers, Bettina Kelsch, Melanie Biedermann, Yvonne P Clever, Silvio Schaffner, Dirk Mahnkopf, Uli Hanisch, Michael Böhm, Bruno Scheller.   

Abstract

BACKGROUND: The purpose of this study was to investigate the elimination of paclitaxel from the arterial wall after a single short administration with a coated balloon. METHODS AND
RESULTS: Slightly oversized paclitaxel-coated balloons (dose 3 or 9 μg/mm(2)) without or with premounted stents were inflated in nonatherosclerotic coronary arteries of either young domestic pigs or adult Goettingen minipigs. The paclitaxel content of plasma, arterial segments, and residual hearts (without treated arteries) was measured for up to 180 days using high-performance liquid chromatography/ultraviolet detection or mass spectrometry. Angiograms were evaluated for lumen narrowing. The paclitaxel concentration in plasma remained <10 ng/mL. In arteries of domestic pigs and minipigs treated with paclitaxel-coated balloons with premounted stents, 10%±5% or 21%±8% of dose, respectively, was initially detected and decreased to 3.5%±3.1% of dose (domestic pig) by Day 7. Within 6 months it fell with a half-life of 1.9 months to 0.40%±0.35%. After 3 months the concentration in the arterial wall was 17±11 μmol/L. Without a stent, drug transfer to the vessel wall was somewhat reduced and elimination faster. Immediately after treatment up to 26%±4% of dose was detected in the residual whole hearts. It dropped with a half-life of 45 days to 1.5%±0.6% of dose (0.3 μmol/L) within 6 months.
CONCLUSIONS: After a single local administration with coated balloons, paclitaxel stays in the vessel wall of pigs long enough to explain persistent inhibition of neointimal proliferation. The pharmacokinetics of paclitaxel does, however, not exclude other reasons for sustained efficacy such as early blocking of processes initiating excessive and prolonged neointimal proliferation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22619258     DOI: 10.1161/CIRCINTERVENTIONS.111.967794

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  29 in total

1.  The use of an occlusion perfusion catheter to deliver paclitaxel to the arterial wall.

Authors:  Marzieh K Atigh; Emily Turner; Uwe Christians; Saami K Yazdani
Journal:  Cardiovasc Ther       Date:  2017-08       Impact factor: 3.023

2.  Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty.

Authors:  Franz X Kleber; Antonia Schulz; Matthias Waliszewski; Telse Hauschild; Michael Böhm; Ulrich Dietz; Bodo Cremers; Bruno Scheller; Yvonne P Clever
Journal:  Clin Res Cardiol       Date:  2014-10-28       Impact factor: 5.460

3.  Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis.

Authors:  Yvonne P Clever; Bodo Cremers; Wolfgang von Scheidt; Michael Böhm; Ulrich Speck; Bruno Scheller
Journal:  Clin Res Cardiol       Date:  2013-09-26       Impact factor: 5.460

4.  HPLC-MS/MS method for quantification of paclitaxel from keratin containing samples.

Authors:  Emily A Turner; Alexandra C Stenson; Saami K Yazdani
Journal:  J Pharm Biomed Anal       Date:  2017-03-10       Impact factor: 3.935

5.  Drug-Coated Balloon Treatment for Delayed Recanalization of Symptomatic Intracranial Artery Occlusion.

Authors:  Wei Zhao; Xi Chu; Yun Song; Jinping Zhang; Lili Sun; Meimei Zheng; Hao Yin; Jun Zhang; Wei Wang; Yao Meng; Ju Han
Journal:  Transl Stroke Res       Date:  2022-04-23       Impact factor: 6.829

6.  Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy.

Authors:  Vijaya B Kolachalama; Stephen D Pacetti; Joseph W Franses; John J Stankus; Hugh Q Zhao; Tarek Shazly; Alexander Nikanorov; Lewis B Schwartz; Abraham R Tzafriri; Elazer R Edelman
Journal:  Circulation       Date:  2013-04-12       Impact factor: 29.690

7.  Balloon-based drug coating delivery to the artery wall is dictated by coating micro-morphology and angioplasty pressure gradients.

Authors:  Abraham R Tzafriri; Benny Muraj; Fernando Garcia-Polite; Antonio G Salazar-Martín; Peter Markham; Brett Zani; Anna Spognardi; Mazen Albaghdadi; Steve Alston; Elazer R Edelman
Journal:  Biomaterials       Date:  2020-08-20       Impact factor: 12.479

Review 8.  [Drug-coated balloons in the treatment of peripheral artery disease (PAD). History and current level of evidence].

Authors:  M Herten; S Stahlhoff; B Imm; E Schönefeld; A Schwindt; G B Torsello
Journal:  Radiologe       Date:  2016-03       Impact factor: 0.635

9.  Adventitial nab-rapamycin injection reduces porcine femoral artery luminal stenosis induced by balloon angioplasty via inhibition of medial proliferation and adventitial inflammation.

Authors:  Warren J Gasper; Cynthia A Jimenez; Joy Walker; Michael S Conte; Kirk Seward; Christopher D Owens
Journal:  Circ Cardiovasc Interv       Date:  2013-11-12       Impact factor: 6.546

10.  Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing.

Authors:  Juan F Granada; Mark Stenoien; Piotr P Buszman; Armando Tellez; Dan Langanki; Greg L Kaluza; Martin B Leon; William Gray; Michael R Jaff; Robert S Schwartz
Journal:  Open Heart       Date:  2014-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.